July 6, 2016 / 11:12 AM / in a year

BRIEF-Immunovaccine says positive interim phase 1 data for DPX-RSV

July 6 (Reuters) - Immunovaccine Inc

* Immunovaccine announces positive interim phase 1 data for Depovax-based respiratory syncytial virus vaccine candidate

* Safety analysis indicates that DPX-RSV was well tolerated among all study participants, with no serious adverse events recorded

* Analysis provides rationale to continue clinical testing of DPX-RSV in future human trials

* Immunovaccine announces positive interim phase 1 data for Depovax-based respiratory syncytial virus vaccine candidate Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below